We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

56 hedge funds and large institutions have $236M invested in Gyre Therapeutics in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 18 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 2

496% more capital invested

Capital invested by funds: $39.7M → $236M (+$197M)

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

300% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 7

60% more funds holding

Funds holding: 35 → 56 (+21)

3.61% more ownership

Funds ownership: 6.66% → 10.27% (+3.6%)

55% less call options, than puts

Call options by funds: $2.29M | Put options by funds: $5.15M

Holders
56
Holders Change
+21
Holders Change %
+60%
% of All Funds
1.28%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.11%
New
28
Increased
18
Reduced
2
Closed
7
Calls
$2.29M
Puts
$5.15M
Net Calls
-$2.86M
Net Calls Change
-$2.86M

Top Buyers

1
SCM
Sio Capital Management
New York
+$23.6M
2
DM
Deerfield Management
New York
+$20.7M
3
ACP
Acuta Capital Partners
California
+$17.5M
4
ACA
Avoro Capital Advisors
New York
+$15.5M
5
RCM
RA Capital Management
Massachusetts
+$12.8M

Top Sellers

1
PVI
Pura Vida Investments
New York
-$818K
2
RJA
Raymond James & Associates
Florida
-$585K
3
UBS Group
UBS Group
Switzerland
-$583K
4
BRWA
B. Riley Wealth Advisors
Florida
-$510K
5
KM
Kalos Management
Georgia
-$222K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACP
1
Acuta Capital Partners
California
$29.8M +$17.5M +93,963 +157%
SCM
2
Sio Capital Management
New York
$29.7M +$23.6M +126,361 +469%
ACA
3
Avoro Capital Advisors
New York
$26.4M +$15.5M +83,217 +156%
DM
4
Deerfield Management
New York
$21.4M +$20.7M +110,747 New
Renaissance Technologies
5
Renaissance Technologies
New York
$14.4M +$5M +26,800 +57%
VMI
6
VHCP Management II
New York
$14.3M +$7.91M +42,394 +135%
NC
7
Nexthera Capital
New York
$13.9M +$5.66M +30,327 +73%
RCM
8
RA Capital Management
Massachusetts
$13.3M +$12.8M +68,656 New
GTC
9
Ghost Tree Capital
New York
$11.6M +$11.2M +60,000 New
Vanguard Group
10
Vanguard Group
Pennsylvania
$9.56M +$6.9M +36,994 +298%
SFM
11
Soros Fund Management
New York
$9.37M +$9.03M +48,409 New
BlackRock
12
BlackRock
New York
$4.8M +$316K +1,692 +7%
JGC
13
J. Goldman & Co
New York
$4.68M +$1.42M +7,606 +46%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$4.55M – – –
IHM
15
Iguana Healthcare Management
New York
$2.58M +$2.49M +13,333 New
T. Rowe Price Associates
16
T. Rowe Price Associates
Maryland
$2.46M +$2.37M +12,728 New
Walleye Trading
17
Walleye Trading
New York
$2.41M +$2.32M +12,435 New
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$2.36M +$2.28M +12,197 New
EWM
19
Essex Woodlands Management
Texas
$2.11M – – –
Millennium Management
20
Millennium Management
New York
$1.62M +$1.56M +8,373 New
Geode Capital Management
21
Geode Capital Management
Massachusetts
$1.62M +$870K +4,663 +126%
PA
22
Perceptive Advisors
New York
$1.42M +$1.37M +7,333 New
Goldman Sachs
23
Goldman Sachs
New York
$1.18M +$1.14M +6,101 New
BRWA
24
B. Riley Wealth Advisors
Florida
$1.08M -$510K -2,733 -33%
EI
25
EAM Investors
California
$941K +$907K +4,861 New
1
2 3

GYRE Hedge Fund Activity: Q1 2018 in Review

56 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2018, worth a combined $236M — up 496% from $39.7M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new GYRE positions and 7 closed out — a net gain of 21 holders — while 18 added to existing stakes and 2 trimmed.

The largest buyer was Sio Capital Management, adding an estimated $23.6M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $818K sold.

  • 56 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2018, up from 35 in Q4 2017.
  • Funds reported $236M of Gyre Therapeutics stock for Q1 2018, up 496% quarter-over-quarter.
  • 28 funds opened new Gyre Therapeutics positions in Q1 2018 and 7 closed out, a net change of +21 holders.
  • The largest Gyre Therapeutics buyer in Q1 2018 was Sio Capital Management, an estimated $23.6M added.
  • The largest Gyre Therapeutics seller in Q1 2018 was Pura Vida Investments, an estimated $818K sold.

Based on aggregated 13F filings for Q1 2018.